TFF Pharmaceuticals’ (TFFP) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of TFF Pharmaceuticals (NASDAQ:TFFPGet Rating) in a research note released on Thursday morning, Marketbeat Ratings reports. The brokerage currently has a $22.00 target price on the stock.

Other analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of TFF Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, May 17th. B. Riley reduced their price objective on TFF Pharmaceuticals from $24.00 to $18.00 and set a buy rating for the company in a report on Tuesday, March 29th.

Shares of TFFP stock opened at $5.49 on Thursday. The firm’s fifty day moving average price is $5.75 and its two-hundred day moving average price is $6.63. The firm has a market capitalization of $139.30 million, a P/E ratio of -4.39 and a beta of 2.14. TFF Pharmaceuticals has a 1 year low of $3.60 and a 1 year high of $12.28.

TFF Pharmaceuticals (NASDAQ:TFFPGet Rating) last posted its earnings results on Wednesday, May 11th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.05. TFF Pharmaceuticals had a negative return on equity of 73.14% and a negative net margin of 24,245.04%. During the same quarter last year, the firm posted ($0.33) EPS. Equities analysts expect that TFF Pharmaceuticals will post -1.23 earnings per share for the current fiscal year.

In other TFF Pharmaceuticals news, Director Aaron G.L. Fletcher acquired 85,000 shares of the company’s stock in a transaction on Monday, May 16th. The stock was acquired at an average cost of $4.86 per share, with a total value of $413,100.00. Following the purchase, the director now directly owns 85,000 shares of the company’s stock, valued at approximately $413,100. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Glenn R. Mattes acquired 16,000 shares of TFF Pharmaceuticals stock in a transaction that occurred on Monday, May 16th. The stock was purchased at an average cost of $4.78 per share, for a total transaction of $76,480.00. Following the completion of the transaction, the chief executive officer now directly owns 36,000 shares in the company, valued at $172,080. The disclosure for this purchase can be found here. Insiders have acquired a total of 651,365 shares of company stock valued at $4,040,003 in the last three months. 9.90% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in TFFP. Parallel Advisors LLC acquired a new stake in shares of TFF Pharmaceuticals during the 4th quarter worth about $26,000. Newbridge Financial Services Group Inc. acquired a new position in TFF Pharmaceuticals during the fourth quarter worth approximately $35,000. Marshall Wace LLP purchased a new stake in TFF Pharmaceuticals in the 3rd quarter valued at approximately $92,000. Goldman Sachs Group Inc. acquired a new stake in shares of TFF Pharmaceuticals in the fourth quarter valued at about $118,000. Finally, Stifel Financial Corp grew its stake in TFF Pharmaceuticals by 31.8% in the 4th quarter. Stifel Financial Corp now owns 14,500 shares of the company’s stock valued at $129,000 after acquiring an additional 3,500 shares during the last quarter. Institutional investors and hedge funds own 18.28% of the company’s stock.

TFF Pharmaceuticals Company Profile (Get Rating)

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.

Featured Stories

Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with's FREE daily email newsletter.